8-K: SELLAS Life Sciences Group Appoints Baker Tilly as New Auditor Following Moss Adams Merger
Auditor Change Announcement
SELLAS Life Sciences Group, Inc. announced the appointment of Baker Tilly US, LLP as its new independent registered public accounting firm, effective June 3, 2025, following the merger of its previous auditor, Moss Adams LLP, with Baker Tilly.
Summary
- SELLAS Life Sciences Group, Inc. (the Company) has appointed Baker Tilly US, LLP as its new independent registered public accounting firm.
- This change is effective June 3, 2025, following the merger of the Company's previous auditor, Moss Adams LLP, with Baker Tilly US, LLP.
- Moss Adams LLP resigned as auditors on June 3, 2025, and the Audit Committee of the Company's Board of Directors approved Baker Tilly's appointment on the same date.
- Moss Adams' audit reports on the Company's consolidated financial statements for the fiscal years ended December 31, 2024, and 2023, did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified, except for an explanatory paragraph regarding a going concern uncertainty.
- There were no disagreements with Moss Adams on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure during the fiscal years 2024, 2023, and the subsequent interim period.
- The Company did not consult with Baker Tilly regarding accounting principles or audit opinions prior to their engagement.
Sentiment
Score: 5
Explanation: The document reports a routine auditor change due to a merger, with no disagreements, which is neutral. However, the explicit mention of a 'going concern uncertainty' in prior audit reports introduces a significant negative element, balancing the overall sentiment to neutral/slightly negative.
Positives
- The transition of auditors was smooth, with no reported disagreements on accounting principles or practices with the outgoing firm, Moss Adams LLP.
- The new auditor, Baker Tilly US, LLP, was engaged without prior consultations that would indicate potential issues or disagreements, suggesting a clean transition.
Negatives
- Moss Adams' audit reports for fiscal years ended December 31, 2024, and 2023, included an explanatory paragraph regarding a 'going concern uncertainty,' indicating potential doubts about the Company's ability to continue as a going concern.
Risks
- The 'going concern uncertainty' noted in the audit reports for 2024 and 2023 by the previous auditor, Moss Adams LLP, indicates a material uncertainty that may cast significant doubt upon the Company's ability to continue as a going concern.
Future Outlook
The document does not provide specific forward-looking statements or guidance regarding the Company's financial performance or strategic direction, beyond the engagement of a new auditor for the fiscal year ending December 31, 2025.
Management Comments
- The Company provided Moss Adams with a copy of this Current Report on Form 8-K prior to its filing with the Securities and Exchange Commission (the Commission) and requested that Moss Adams furnish the Company with a letter addressed to the Commission stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree.
Industry Context
This filing primarily concerns a routine corporate governance matter related to an auditor change due to a merger of accounting firms. It does not provide specific insights into broader industry trends within the biotechnology or pharmaceutical sectors, beyond the general operational context of a life sciences company.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Auditor Appointment | The Audit Committee of the Company's Board of Directors accepted the resignation of Moss Adams LLP and approved the appointment of Baker Tilly US, LLP as the successor independent registered public accounting firm. | 2025-06-03 | Ensures continuity of independent audit services following a merger of the previous accounting firm, maintaining compliance with regulatory requirements. |
Stakeholder Impact
- Shareholders: The change in auditors due to a merger is generally a neutral event, but the disclosure of a 'going concern uncertainty' in prior audit reports could raise concerns about the Company's financial viability.
- Management: Ensures compliance with SEC regulations regarding independent audits.
Next Steps
- Baker Tilly US, LLP will serve as the Company's new independent registered public accounting firm for the fiscal year ending December 31, 2025.
Key Dates
| Date | Description |
|---|---|
| 2023-12-31 | End of fiscal year for which Moss Adams issued an audit report with a going concern uncertainty. |
| 2024-12-31 | End of fiscal year for which Moss Adams issued an audit report with a going concern uncertainty. |
| 2025-06-03 | Date of merger between Moss Adams LLP and Baker Tilly US, LLP; Moss Adams' resignation accepted; Baker Tilly's appointment approved by Audit Committee. |
| 2025-06-06 | Date of Moss Adams' letter to the SEC confirming agreement with the 8-K statements; Date of signing of the 8-K filing. |
Recommendation
holdKeywords
SELLAS Life Sciences Group, SLS, auditor change, Baker Tilly, Moss Adams, SEC filing, Form 8-K, accounting firm, going concern, biotechnology, pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.